If the tariff-loving Trump goes ahead with his plans, it will hit AstraZeneca - the most valuable company on the UK stock market - and also rival GSK, another stalwart of the FTSE 100.
If the tariff-loving Trump goes ahead with his plans, it will hit AstraZeneca - the most valuable company on the UK stock market - and also rival GSK, another stalwart of the FTSE 100.
Zantac went on sale in the UK in 1981. But in 2019, GSK withdrew it in the UK and US over fears that the ingredient ranitidine created a carcinogenic chemical
The trailblazing study will use the data from up to 1.4million NHS patients to test whether its shingles vaccine reduces the risk of the degenerative disease, which is the country's biggest killer.